What is Chromafora?
Founded in Stockholm, Sweden, Chromafora specializes in providing comprehensive expertise in phosphorus chemistry and the chemistry of nucleic acid components. The company serves a global market, leveraging a competent and innovative team with deep experience in nucleoside/nucleotide synthesis, oligonucleotide synthesis, and medicinal chemistry focused on nucleoside and nucleotide-based drugs. Their specialties also extend to the synthesis of phosphines, phosphonates, phosphoroamidites, and phospholipids. Chromafora addresses a critical need for specialized phosphorus chemistry knowledge, offering expert services to organizations that may not require a full-time in-house specialist, thereby saving them time, money, and effort.
How much funding has Chromafora raised?
Chromafora has raised a total of $23.1M across 1 funding round:
Other Financing Round
$23.1M
Other Financing Round (2025): $23.1M with participation from European Investment Bank
Key Investors in Chromafora
European Investment Bank
The European Investment Bank, established in 1958 and headquartered in Luxembourg, is the European Union's nonprofit long-term lending and finance institution, likely supporting strategic European enterprises.
What's next for Chromafora?
The recent major strategic investment signals a new phase of growth and development for Chromafora. This capital infusion is expected to fuel further innovation in their specialized chemical synthesis capabilities and expand their global reach. The company is well-positioned to capitalize on its unique expertise, potentially leading to advancements in drug discovery and materials science, reinforcing its status as a key player in the niche field of phosphorus chemistry.
See full Chromafora company page
